BACKGROUND AND AIMS: Ileocaecal resection (ICR) is frequent in paediatric patients with Crohn's disease (pCD). Despite rates of reoperation being low, the risk of clinical or endoscopic post-operative recurrence (POR) is high; effective medical strategies to prevent POR are thus needed. The aim of this systematic review (SR) was to identify and evaluate the published literature on post-operative medical prevention of POR in pCD to draft a possible therapy guide for pCD patients undergoing ICR. METHODS: We performed an SR according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards and registered it in the PROSPERO database (ID: CRD42024533855). The population, intervention, control, outcome (PICO) model was focussed on post-surgical medical prevention of POR in pCD with clearly expressed definition of recurrence (endoscopically using a standardized scoring system (e.g. Rutgeerts score) or by laboratory markers, for example, faecal calprotectin (F-CPT), C-reactive protein (CRP) or by histological findings or by clinical activity indexes [e.g. weighted paediatric Crohn's disease activity index - (w)PCDAI]. From inception until 29 February 2024, the following databases were searched: PubMed/MEDLINE, Scopus/Embase, Web of Sciences, Evidence-Based Medicine Reviews (including Cochrane), Cochrane Central Registrar of controlled Trials (CENTRAL), ClinicalTrials.gov and EudraCT. Retrieved articles were evaluated for eligibility and finally selected publications for risk of bias using ROBINS-I tool. RESULTS: Out of 811 publications identified by the search, only 5 fulfilled inclusion criteria of the SR. None of the studies fully answered our PICO question. The studies were overall of poor quality and the heterogeneity of the data did not allow us to perform meta-analysis, detailed statistical analysis or formal synthesis of data. Adverse events of post-operative medication were not described in any of the included studies. Existing guidelines of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), North American Society for Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), European Crohn's and Colitis Organisation (ECCO) and American Gastroenterological Association (AGA) were reviewed and paediatric therapy guide for pCD undergoing ICR was drafted with respect to recent SRs and meta-analyses in adult population and including scarce paediatric data identified by our SR. As pCD patients undergoing ICR are a high-risk population, they should not be left untreated post-operatively. Anti-tumour necrosis factor (anti-TNF) drugs should be considered as first-line therapy in the majority of patients. Non-anti-TNF biologics should be considered in case of anti-TNF failure. Regular endoscopic monitoring starting at 6 months after the surgery and supported by regular F-CPT evaluation should be used to identify early endoscopic recurrence and to escalate the treatment. CONCLUSION: Our SR revealed that there is wide variability in treatment strategies in children, and high-quality data are generally lacking. At the moment, paediatric prophylaxis of POR should be guided by available adult evidence with respect to the high-risk nature of pCD. Extensive research in pCD should be encouraged.

Department of Paediatric Surgery 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Paediatrics 2nd Faculty of Medicine Gastroenterology and Nutrition Unit Charles University and University Hospital Motol 5 Uvalu 84 15006 Prague Czech Republic

See more in PubMed

Kim HJ, Oh SH, Kim DY, Lee HS, Park SH, Yang SK, et al. Clinical characteristics and long-term outcomes of paediatric Crohn’s disease: a single-centre experience. J Crohns Colitis. 2017;11(2):157–64. PubMed DOI

Rinawi F, Assa A, Hartman C, Mozer Glassberg Y, Friedler VN, Rosenbach Y, et al. Incidence of bowel surgery and associated risk factors in pediatric-onset Crohn’s disease. Inflamm Bowel Dis. 2016;22(12):2917–23. PubMed DOI

Yerushalmy-Feler A, Assa A. Pharmacological prevention and management of postoperative relapse in pediatric Crohn’s disease. Paediatr Drugs. 2019;21(6):451–60. PubMed DOI

Zarubova K, Hradsky O, Copova I, Rouskova B, Pos L, Skaba R, et al. Endoscopic recurrence 6 months after ileocecal resection in children with Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr. 2017;65(2):207–11. PubMed DOI

Lee KE, Cantrell S, Shen B, Faye AS. Post-operative prevention and monitoring of Crohn’s disease recurrence. Gastroenterol Rep (Oxf). 2022;10: goac070. PubMed DOI PMC

Beelen EMJ, Nieboer D, Arkenbosch JHC, Regueiro MD, Satsangi J, Ardizzone S, et al. Risk prediction and comparative efficacy of anti-TNF vs thiopurines, for preventing postoperative recurrence in Crohn’s disease: a pooled analysis of 6 trials. Clin Gastroenterol Hepatol. 2022;20(12):2741–52 (e6). PubMed DOI

Liu C, Li N, Zhan S, Tian Z, Wu D, Li T, et al. Anti-TNFalpha agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era? Expert Opin Biol Ther. 2021;21(11):1509–24. PubMed DOI

Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, et al. Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn’s disease? Systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(4):864–72. PubMed DOI

Bachour SP, Click BH. Clinical update on the prevention and management of postoperative Crohn’s disease recurrence. Curr Gastroenterol Rep. 2024;26(2):41–52. PubMed DOI

Gisbert JP, Chaparro M. Anti-TNF agents and new biological agents (vedolizumab and ustekinumab) in the prevention and treatment of postoperative recurrence after surgery in Crohn’s disease. Drugs. 2023;83(13):1179–205. PubMed DOI PMC

Steinberg JM, Chowdhury R, Sharma S, Charabaty A. Biologics, small molecule therapies and surgery in small bowel Crohn’s disease. Curr Opin Gastroenterol. 2024;40(3):203–8. PubMed DOI

Amil-Dias J, Kolacek S, Turner D, Paerregaard A, Rintala R, Afzal NA, et al. Surgical management of Crohn disease in children: guidelines from the paediatric IBD porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2017;64(5):818–35. PubMed DOI

Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795–806. PubMed DOI

Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919. PubMed DOI PMC

Spencer EA, Jarchin L, Rolfes P, Khaitov S, Greenstein A, Dubinsky MC. Outcomes of primary ileocolic resection for pediatric Crohn disease in the biologic era. J Pediatr Gastroenterol Nutr. 2021;73(6):710–6. PubMed DOI PMC

Dreznik Y, Samuk I, Shouval DS, Paran M, Matar M, Shamir R, et al. Recurrence rates following ileo-colic resection in pediatric patients with Crohn’s disease. Pediatr Surg Int. 2023;39(1):83. PubMed DOI

Glenisson M, Bonnard A, Berrebi D, Belarbi N, Viala J, Martinez-Vinson C. Complications and disease recurrence after ileocecal resection in pediatric Crohn’s disease: a retrospective study. Eur J Pediatr Surg. 2024;34(3):253–60. PubMed DOI

Hojsak I, Kolacek S, Hansen LF, Bronsky J, Piekkala M, Lionetti P, et al. Long-term outcomes after elective ileocecal resection in children with active localized Crohn’s disease—a multicenter European study. J Pediatr Surg. 2015;50(10):1630–5. PubMed DOI

Weigl E, Schwerd T, Lurz E, Haberle B, Koletzko S, Hubertus J. Children with localized Crohn’s disease benefit from early ileocecal resection and perioperative anti-tumor necrosis factor therapy. Eur J Pediatr Surg. 2024;34(3):236–44. PubMed DOI

Splawski JB, Pffefferkorn MD, Schaefer ME, Day AS, Soldes OS, Ponsky TA, et al. NASPGHAN clinical report on postoperative recurrence in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65(4):475–86. PubMed DOI

Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, et al. ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohns Colitis. 2018;12(1):1–16. PubMed

Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd european evidence-based consensus on the diagnosis and management of crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11(2):135–49. PubMed DOI

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. PubMed DOI

Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S, et al. American gastroenterological association institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152(1):271–5. PubMed DOI

Gallagher J, Rosh JR, Sahn B. The future of advanced therapies for pediatric Crohn’s disease. Paediatr Drugs. 2023;25(6):621–33. PubMed DOI

Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2019;6(6): CD008414. PubMed

Peyrin-Biroulet L, Deltenre P, Ardizzone S, D’Haens G, Hanauer SB, Herfarth H, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104(8):2089–96. PubMed DOI

Gjuladin-Hellon T, Iheozor-Ejiofor Z, Gordon M, Akobeng AK. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2019;8(8): CD010233. PubMed

Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150(7):1568–78. PubMed DOI

Hirsch A, Scapa E, Fliss-Isakov N, Tulchinsky H, Itzkowitz E, Kariv Y, et al. Early initiation of adalimumab significantly diminishes postoperative Crohn’s disease endoscopic recurrence and is superior to 6-mercaptopurine therapy: an open-label, randomized controlled study. J Clin Med. 2023;12(24):7600. PubMed DOI PMC

Vuitton L, Peyrin-Biroulet L. Pharmacological prevention of postoperative recurrence in Crohn’s disease. Drugs. 2020;80(4):385–99. PubMed DOI

Gangwani MK, Nawras M, Aziz M, Rani A, Priyanka F, Dahiya DS, et al. Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn’s disease: a systematic review and meta-analysis. Ann Gastroenterol. 2023;36(3):293–9. PubMed PMC

Jain SR, Ow ZGW, Chin YH, Lim WH, Kong G, Tham HY, et al. Quantifying the rate of recurrence of postoperative Crohn’s disease with biological therapy. A meta-analysis. J Dig Dis. 2021;22(7):399–407. PubMed DOI

Assa A, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, et al. Anti-TNFalpha treatment after surgical resection for Crohn’s disease is effective despite previous pharmacodynamic failure. Inflamm Bowel Dis. 2017;23(5):791–7. PubMed DOI

Buisson A, Cannon L, Umanskiy K, Hurst RD, Hyman NH, Sakuraba A, et al. Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease. Intest Res. 2022;20(3):303–12. PubMed DOI

Dotlacil V, Bronsky J, Hradsky O, Frybova B, Coufal S, Skaba R, et al. The impact of anti-tumor necrosis factor alpha therapy on postoperative complications in pediatric Crohn’s disease. Eur J Pediatr Surg. 2020;30(1):27–32. PubMed DOI

Fasulo E, D’Amico F, Osorio L, Allocca M, Fiorino G, Zilli A, et al. The management of postoperative recurrence in Crohn’s disease. J Clin Med. 2023;13(1):119. PubMed DOI PMC

Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2022;71(1):34–42. PubMed DOI

Lerchova T, Hradsky O, Kulich M, Veres G, Dias JA, Sladek M, et al. Prediction of thiopurine failure in pediatric Crohn’s disease: pediatric IBD porto group of ESPGHAN. Pediatr Res. 2023;93(6):1659–66. PubMed DOI

van Gennep S, Konte K, Meijer B, Heymans MW, D’Haens GR, Lowenberg M, et al. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther. 2019;50(5):484–506. PubMed DOI

Candia R, Naimark D, Sander B, Nguyen GC. Cost-utility analysis: thiopurines plus endoscopy-guided biological step-up therapy is the optimal management of postoperative Crohn’s disease. Inflamm Bowel Dis. 2017;23(11):1930–40. PubMed DOI

Frieri G, Valvano M, Frassino S, Faenza S, Cesaro N, Amicucci G, et al. Prophylactic treatment with vedolizumab in the prevention of postoperative recurrence (POR) in high-risk Crohn’s patients. J Clin Med. 2023;12(9):3130. PubMed DOI PMC

DHaens G. Prevention of postoperative recurrence of Crohn's disease with vedolizumab: first results of the prospective placebo-controlled randomised trial REPREVIO 2023. Available from: https://academic.oup.com/ecco-jcc/article/17/Supplement_1/i19/7009310 .

Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, et al. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn’s disease. United Eur Gastroenterol J. 2021;9(5):552–60. DOI

Axelrad JE, Li T, Bachour SP, Nakamura TI, Shah R, Sachs MC, et al. Early initiation of antitumor necrosis factor therapy reduces postoperative recurrence of Crohn’s disease following ileocecal resection. Inflamm Bowel Dis. 2023;29(6):888–97. PubMed DOI

Manosa M, Fernandez-Clotet A, Nos P, Martin-Arranz MD, Mancenido N, Carbajo A, et al. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn’s disease: Results from the ENEIDA registry. Dig Liver Dis. 2023;55(1):46–52. PubMed DOI

Mourad FH, Maalouf RG, Aoun R, Gustavo Kotze P, Hashash JG. Are the new biologics effective in the management of postoperative Crohn’s disease? Inflamm Bowel Dis. 2024;30(3):459–69. PubMed DOI

Chong C, Rahman A, Loonat K, Sagar RC, Selinger CP. Current smoking habits in British IBD patients in the age of e-cigarettes. BMJ Open Gastroenterol. 2019;6(1): e000309. PubMed DOI PMC

Sheehan GT, Twardus SW, Cagan A, Ananthakrishnan AN. E-cigarette use and disease outcomes in inflammatory bowel diseases: a case-control study. Dig Dis Sci. 2023;68(1):208–13. PubMed DOI

Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63. PubMed DOI

Luglio G, Kono T. Surgical techniques and risk of postoperative recurrence in CD: a game changer? Inflamm Intest Dis. 2022;7(1):21–7. PubMed DOI

Dasharathy SS, Limketkai BN, Sauk JS. What’s new in the postoperative management of Crohn’s disease? Dig Dis Sci. 2022;67(8):3508–17. PubMed DOI

Bak MTJ, Ten Bokkel HS, Erler NS, Bodelier AGL, Dijkstra G, Romberg-Camps M, et al. Prognostic value of the modified rutgeerts score for long-term outcomes after primary ileocecal resection in Crohn’s disease. Am J Gastroenterol. 2024;119(2):306–12. PubMed DOI

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–17. PubMed DOI

Yzet C, Riault C, Brazier F, Grados L, Nguyen-Khac E, Chatelain D, et al. Positive margins and plexitis increase the risk of recurrence after ileocecal resection: a systematic review and meta-analysis. Dig Liver Dis. 2023;55(12):1611–20. PubMed DOI

Zarubova K, Fabian O, Hradsky O, Lerchova T, Mikus F, Dotlacil V, et al. Predictive value of tissue calprotectin for disease recurrence after ileocecal resection in pediatric Crohn’s disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022;166(3):297–303. PubMed DOI

Zhuang X, Tian Z, Li N, Mao R, Li X, Zhao M, et al. Gut microbiota profiles and microbial-based therapies in post-operative Crohn’s disease: a systematic review. Front Med (Lausanne). 2020;7: 615858. PubMed DOI

Hammoudi N, Auzolle C, Tran Minh ML, Boschetti G, Bezault M, Buisson A, et al. Postoperative endoscopic recurrence on the neoterminal ileum but not on the anastomosis is mainly driving long-term outcomes in Crohn’s disease. Am J Gastroenterol. 2020;115(7):1084–93. PubMed DOI

Hanzel J, Drobne D. Contemporary management of postoperative Crohn’s disease after ileocolonic resection. J Clin Med. 2022;11(22):6746. PubMed DOI PMC

Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785–92. PubMed DOI

Alvisi P, Faraci S, Scarallo L, Congiu M, Bramuzzo M, Illiceto MT, et al. Major abdominal surgery for pediatric Crohn’s disease in the anti-TNF era: 10-year analysis of data from the IBD registry of Italian society of pediatric gastroenterology, hepatology, and nutrition. Inflamm Bowel Dis. 2024. https://doi.org/10.1093/ibd/izad310 . PubMed DOI

Dotlacil V, Lerchova T, Coufal S, Kucerova B, Schwarz J, Hradsky O, et al. Comparison of laparoscopic and open ileocecal resection for Crohn’s disease in children. Pediatr Surg Int. 2023;39(1):140. PubMed DOI PMC

Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2020;14(2):155–68. PubMed DOI

Dotlacil V, Lerchova T, Lengalova M, Kucerova B, Schwarz J, Hradsky O, et al. Kono-S anastomosis in Crohn’s disease: initial experience in pediatric patients. Pediatr Surg Int. 2024;40(1):67. PubMed DOI